Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical OncologyGlobeNewsWire • 03/22/21
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/24/21
Kura Oncology Receives FDA Breakthrough Therapy Tag For Tipifarnib In Head & Neck CancerBenzinga • 02/24/21
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell CarcinomaGlobeNewsWire • 02/24/21
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional SharesGlobeNewsWire • 12/11/20
Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without RisksSeeking Alpha • 12/10/20
Kura Oncology Announces Pricing of $300 Million Public Offering of Common StockGlobeNewsWire • 12/09/20
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual MeetingGlobeNewsWire • 12/05/20
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/07/20
Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Kα Inhibitor in Head and Neck Squamous Cell CarcinomaGlobeNewsWire • 10/26/20